ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone replacement therapy is associated with an increased risk of urolithiasis
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 143232" data-attributes="member: 13851"><p><strong>Abstract </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Purpose</span></strong> To determine whether TRT in men with hypogonadism is associated with an increased risk of urolithiasis.</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Methods</span></strong> We conducted a population-based matched cohort study utilizing data sourced from the Military Health System Data Repository (a large military-based database that includes beneficiaries of the TRICARE program). This included men aged 40–64 years with no prior history of urolithiasis who received continuous TRT for a diagnosis of hypogonadism between 2006 and 2014. Eligible individuals were matched using both demographics and comorbidities to TRICARE enrollees who did not receive TRT. The primary outcome was 2-year absolute risk of a stone-related event, comparing men on TRT to non-TRT controls.</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results </span></strong>There were 26,586 pairs in our cohort. Four hundred and eighty-two stone-related events were observed at 2 years in the non-TRT group versus 659 in the TRT group. Log-rank comparisons showed this to be a statistically significant difference in events between the two groups (p<0.0001). This difference was observed for topical (p<0.0001) and injection (p=0.004) therapy-type subgroups, though not for pellet (p=0.27). There was no significant difference in stone episodes based on secondary polycythemia diagnosis, which was used as an indirect indicator of higher on-treatment testosterone levels (p=0.14).</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Conclusion </span></strong>We observed an increase in 2-year absolute risk of stone events among those on TRT compared to those who did not undergo this hormonal therapy. These findings merit further investigation into the pathophysiologic basis of our observation and consideration by clinicians when determining the risks and benefits of placing patients on TRT.</p><p></p><p></p><p></p><p></p><p></p><p>In conclusion, controversy regarding the various risks of TRT persists. <strong>However, in this large retrospective cohort study, we establish a statistically significant association between TRT and stone events at 2-year follow-up. <span style="color: rgb(184, 49, 47)">Given this is the first study to specifically examine the relationship of TRT with stone events, these data should be considered alongside other known risks and benefits as clinicians select appropriate patients for implementation of TRT. </span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 143232, member: 13851"] [B]Abstract [/B] [B][COLOR=rgb(184, 49, 47)]Purpose[/COLOR][/B][COLOR=rgb(184, 49, 47)] [/COLOR]To determine whether TRT in men with hypogonadism is associated with an increased risk of urolithiasis. [B][COLOR=rgb(184, 49, 47)]Methods[/COLOR][/B] We conducted a population-based matched cohort study utilizing data sourced from the Military Health System Data Repository (a large military-based database that includes beneficiaries of the TRICARE program). This included men aged 40–64 years with no prior history of urolithiasis who received continuous TRT for a diagnosis of hypogonadism between 2006 and 2014. Eligible individuals were matched using both demographics and comorbidities to TRICARE enrollees who did not receive TRT. The primary outcome was 2-year absolute risk of a stone-related event, comparing men on TRT to non-TRT controls. [B][COLOR=rgb(184, 49, 47)]Results [/COLOR][/B]There were 26,586 pairs in our cohort. Four hundred and eighty-two stone-related events were observed at 2 years in the non-TRT group versus 659 in the TRT group. Log-rank comparisons showed this to be a statistically significant difference in events between the two groups (p<0.0001). This difference was observed for topical (p<0.0001) and injection (p=0.004) therapy-type subgroups, though not for pellet (p=0.27). There was no significant difference in stone episodes based on secondary polycythemia diagnosis, which was used as an indirect indicator of higher on-treatment testosterone levels (p=0.14). [B][COLOR=rgb(184, 49, 47)]Conclusion [/COLOR][/B]We observed an increase in 2-year absolute risk of stone events among those on TRT compared to those who did not undergo this hormonal therapy. These findings merit further investigation into the pathophysiologic basis of our observation and consideration by clinicians when determining the risks and benefits of placing patients on TRT. In conclusion, controversy regarding the various risks of TRT persists. [B]However, in this large retrospective cohort study, we establish a statistically significant association between TRT and stone events at 2-year follow-up. [COLOR=rgb(184, 49, 47)]Given this is the first study to specifically examine the relationship of TRT with stone events, these data should be considered alongside other known risks and benefits as clinicians select appropriate patients for implementation of TRT. [/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone replacement therapy is associated with an increased risk of urolithiasis
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top